AI-Enabled Stethoscope Boosts Diagnosis of Pregnancy-Related Cardiomyopathy
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 10, 2024 -- In pregnant and postpartum women, artificial intelligence (AI)-guided screening using a digital stethoscope improves the diagnosis of pregnancy-related cardiomyopathy, according to a study published online Sept. 2 in Nature Medicine to coincide with the European Society of Cardiology Congress 2024, held from Aug. 30 to Sept. 2 in London.
Demilade A. Adedinsewo, M.B.,Ch.B., from the Mayo Clinic in Jacksonville, Florida, and colleagues randomly assigned 1,195 pregnant and postpartum Nigerian women to usual care or AI-guided screening to assess its impact on the diagnosis of left ventricular systolic dysfunction (LVSD) in the perinatal period.
The researchers found that when using the AI-enabled digital stethoscope, the number of identified participants with LVSD detection was 24 out of 587 (4.1 percent) versus 12 out of 608 (2.0 percent) patients (intervention versus control odds ratio [OR], 2.12; 95 percent confidence interval [CI], 1.05 to 4.27). With the 12-lead AI-electrocardiogram model, the number of identified participants with LVSD detection was 20 out of 587 (3.4 percent) versus 12 out of 608 (2.0 percent) patients (OR, 1.75; 95 percent CI, 0.85 to 3.62).
"This study provides evidence that we can better detect peripartum cardiomyopathy among women in Nigeria. However, there are more questions to be answered," Adedinsewo said in a statement. "Our next steps would be to evaluate usability and adoption of this tool by Nigerian healthcare providers (including doctors and nurses) and importantly, its impact on patient care."
Several authors disclosed ties to relevant organizations.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Rx Up for Stimulants and Antidepressants, Down for Opioids, 2019 to 2022
MONDAY, Sept. 16, 2024 -- Overall prescription volumes for stimulant and antidepressant medications increased from 2019 to 2022, while prescription volume for opioids decreased...
Opt-Out Syphilis Screening in ED Improves Screening, Diagnosis
FRIDAY, Sept. 13, 2024 -- Implementation of opt-out emergency department syphilis screening leads to a dramatic increase in screening and diagnosis, especially among pregnant...
Tusamitamab Ravtansine Does Not Extend Survival With Nonsquamous NSCLC
FRIDAY, Sept. 13, 2024 -- Tusamitamab ravtansine (tusa rav), an immunoconjugate, does not improve progression-free survival (PFS) in patients with previously treated advanced...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.